---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-169713"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T00:59:19.766516+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.68
calibrated_materiality_score: 0.68
confidence: "high"
source: SEC EDGAR
---

# Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront

## Summary
- Upfront payment $35M plus regulatory milestone payments and royalties.
- Pair includes 177Lu-DOTA-RM2 (therapeutic) and 68Ga-DOTA-RM2 (diagnostic) targeting GRPR in prostate, breast, and other cancers.
- Lantheus plans Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer in 2025; 68Ga-DOTA-RM2 as companion diagnostic.
- Strengthens Lantheus' prostate cancer portfolio and expands pipeline to include breast cancer.
- Life Molecular will complete ongoing Phase 1/2a dose escalation study in collaboration with Lantheus.

## SEC filing metadata
- accession: 0001193125-24-169713
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.68
- calibrated_materiality_score: 0.68
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312524169713/0001193125-24-169713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312524169713/d651116d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-169713
- JSON: https://secwatch.observer/filing/0001193125-24-169713.json
- Plain text: https://secwatch.observer/filing/0001193125-24-169713.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.